Jubilant inks licensing deal with Gilead for Remdesivir
India, May 13 -- Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited ("Jubilant"), has entered into a non-exclusive Licensing Agreement withGilead Sciences, Inc.that will grant Jubilant the right to register, manufacture and sell Gilead's investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India.
These countries consist of nearly all low-income and lower middle-income countries, as well as several upper-middle and high-income countries that face significant obstacles to healthcare access. Under the licensing agreement, Jubilant will have the right to receive a technology transfer of th...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.